Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan

To assess whether the improvement in hepatic steatosis was associated with better glycemic control, we examined changes in CAP and HbA1C values in patients according to their lobeglitazone responsiveness (Fig. 2C and 2D ). After the 24-week treatment, the mean CAP value in the lobeglitazone-responder group decreased from 320.9 dB/m to 282.6 dB/m, whereas the mean CAP value in the lobeglitazone-non-responder group increased from 299. These data indicate that the improvement in hepatic steatosis by lobeglitazone is independent of its glucose-lowering effect. Changes in glycemic, lipid, and hepatic profiles after lobeglitazone treatment for 24 weeks Among secondary endpoints, the 24-week treatment with lobeglitazone significantly improved glycemic parameters, such as GA and the fasting levels of glucose and insulin (P < 0.001) ( Table 2 ). Insulin resistance, as assessed by HOMAIR, was ameliorated from 5.5 to 3.4 by lobeglitazone treatment. Among lipid profile components, lobeglitazone treatment significantly increased HDL-C (P = 0.001) and decreased TG levels (P = 0.019). However, TC and LDL-C levels did not change. All components of the hepatic profile, including AST, ALT, and γGTP, showed significantly decreased levels after 24 weeks of treatment (P < 0.01). In addition, LSM and hsCRPs values were marginally decreased, whereas average body weight increased by 1.4 kg after lobeglitazone treatment. At the 24-week time point, drug compliance was 98.2%.